Bone Biologics Corp Receives Nasdaq Notice for Minimum Bid Price Deficiency

What Happened
Bone Biologics Corporation (BBLG) announced on an 8-K (Item 3.01) that on September 10, 2026 it received a letter from Nasdaq’s Listing Qualifications Staff stating the company no longer meets Nasdaq Listing Rule 5550(a)(2) because its common stock closed below $1 for the last 30 consecutive business days. Nasdaq has given a 180-calendar-day compliance period through March 9, 2027 for the company to regain compliance.

Key Details

• Nasdaq notice received: September 10, 2026 (Item 3.01).
• Compliance mechanics: must have a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days within the 180-day period (deadline March 9, 2027).
• Possible relief: if eligible, the company may request a second 180-day period by meeting market-value and other initial listing standards (excluding the bid-price rule) and notifying Nasdaq.
• Company actions: no immediate listing change; Bone Biologics intends to monitor the stock price and will ask shareholders at its upcoming annual meeting to approve a reverse stock split, which the Board could authorize if approved to try to regain compliance.

Why It Matters
A continued failure to meet Nasdaq’s $1 minimum bid requirement could lead to delisting proceedings, which can reduce liquidity, investor interest, and access to capital. The company has until March 9, 2027 to cure the deficiency (or seek a possible second extension) and is pursuing a potential reverse stock split as a remedy. The filing also contains customary forward-looking statements about these plans and associated risks.